BioSyent Q2 2023 Earnings Report

BioSyent EPS Results

• Actual EPS: C$0.12
• Consensus EPS: C$0.12
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

BioSyent Revenue Results

• Actual Revenue: $7.96 million
• Expected Revenue: $7.70 million
• Beat/Miss: Beat by +$260.00 thousand
• YoY Revenue Growth: N/A

BioSyent Announcement Details

• Quarter: Q2 2023
• Date: 8/22/2023
• Time: N/A

BioSyent (CVE:RX), together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.